Perioperative Anticoagulation and Mesh Sling Planning
A 58-year-old woman with stress urinary incontinence is scheduled for a retropubic midurethral sling. She has atrial fibrillation on apixaban, hypertension, and a BMI of 34. Her CHA2DS2-VASc score is 3. She is anxious about stopping her blood thinner and asks whether the surgery can be done without interrupting it. Her last apixaban dose is scheduled the morning of surgery per her cardiologist's instruction. She also takes naproxen for knee pain and a daily aspirin.
1. How do you approach perioperative anticoagulation for this procedure?
Read the worked answer
This requires coordinated, procedure-specific planning, not a blanket rule:
- Apixaban is typically held for a period before surgery based on renal function and bleeding risk; a retropubic sling is a moderate-to-high bleeding risk procedure because of the retropubic space and mesh passage. The exact hold interval should follow the procedural bleeding-risk category and her renal function, and should be confirmed with the prescribing cardiologist and/or anesthesia.
- Do not simply accept 'take it the morning of surgery' - that instruction is unsafe for this procedure. Clarify with the cardiologist and document the agreed plan.
- Bridging with heparin is generally not needed for most DOAC interruptions, but the decision belongs to the anticoagulation team; document their input.
- Naproxen and aspirin should be reviewed: NSAIDs increase bleeding and are usually stopped preoperatively; aspirin continuation depends on whether it is for primary or secondary prevention and should be a deliberate decision, not an afterthought.
- Resume timing postoperatively depends on hemostasis and bleeding risk; plan it in advance and document.
A team approach with cardiology/anesthesia and a written plan is the standard.
2. What would you tell her about the risks of continuing versus interrupting anticoagulation?
Read the worked answer
Frame it as a balance of two real risks:
- Continuing anticoagulation raises the risk of intraoperative and postoperative bleeding, including retropubic hematoma, which can be serious and may require reoperation or transfusion. Even a small hematoma can compromise the sling or cause voiding dysfunction.
- Interrupting anticoagulation raises the risk of thromboembolism/stroke, which for her CHA2DS2-VASc of 3 is not negligible.
The goal is a short, well-timed interruption with the prescribing team's agreement, not stopping the drug indefinitely. Explain that the plan is individualized to her renal function and the bleeding risk of the operation, and that the team will confirm the exact timing.
Also address her anxiety directly: ask what she is most worried about, provide the written plan, and give her a contact for questions before surgery.
3. What postoperative considerations are specific to her comorbidities?
Read the worked answer
- VTE prophylaxis: with BMI 34 and atrial fibrillation, she needs risk-stratified mechanical and/or pharmacologic prophylaxis, balanced against bleeding risk and coordinated with her anticoagulation plan.
- Early ambulation and hydration.
- Wound and mesh considerations: obesity increases wound complications and may affect sling outcomes; counsel on weight and wound care.
- Voiding trial before discharge with a plan for catheter management if she retains.
- Bleeding surveillance: monitor for retropubic hematoma (pain, dropping hemoglobin, urinary retention).
- Resume anticoagulation per the agreed plan, with clear instructions on when to call.
- Medication reconciliation: ensure naproxen is not restarted inappropriately and that aspirin decisions are documented.
- Follow-up to review wound, voiding, and continence.